Johnson & Johnson stock gains on HSBC price target hike to USD 320
Published on 09/11/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock (ISIN US4781601046) is trading close to recent highs after a fresh vote of confidence from HSBC, which lifted its price target to USD 320 on September 10, 2026, while maintaining a Buy rating on the shares.
HSBC raises price target to USD 320
According to GuruFocus on September 10, 2026, HSBC raised its price target for Johnson & Johnson from USD 290.00 to USD 320.00 and reiterated a Buy rating, implying an increase of 10.34 percent in the target range.
The same overview notes that Johnson & Johnson shares were trading at USD 268.82 at the time of the HSBC update, which GuruFocus estimates to be about 39.2 percent above its proprietary GF Value of USD 193.18, underlining a perceived valuation premium relative to fundamental metrics.
Recent earnings and fundamentals
For the latest reported quarter, Q2 2026 ended June 30, 2026, Johnson & Johnson generated total revenue of USD 25.32 billion, up 5.52 percent year-on-year, highlighting mid-single-digit top-line growth across its portfolio according to data compiled by CNN.
In the same Q2 2026 period, net income came in at USD 5.53 billion, an increase of 7.41 percent versus the prior year, while earnings per share reached USD 2.27, up 0.92 percent year-on-year, with a reported net profit margin of 21.86 percent that improved by 6.28 percent compared with the previous year, as shown in the CNN metrics.
On a trailing twelve-month basis, Johnson & Johnson recorded total revenue of USD 94.18 billion and net income of USD 26.80 billion, with full-year EPS of USD 11.03, and CNN data indicate that total revenue increased 6.03 percent versus the prior year while EPS rose by 90.56 percent, reflecting a strong rebound in profitability after earlier headwinds.
Additional analyst signals and valuation context
Alongside the HSBC call, RBC Capital Markets continues to rate Johnson & Johnson stock as a Buy with a target price of USD 287, as reported by Futunn on September 11, 2026, suggesting that major houses remain constructive on the shares even at current levels.
GuruFocus assigns Johnson & Johnson a GF Score of 83 out of 100, which it interprets as a sign of strong overall performance potential, but the service also flags that, at USD 268.82 per share versus a GF Value of USD 193.18, the stock appears significantly overvalued on its internal model, creating a tension between analyst optimism and valuation discipline.
Insider activity tracked by GuruFocus shows insider selling of approximately USD 70.19 million over the last three months, which some investors may read as a moderating signal after the strong share-price performance, even though such sales can also reflect portfolio diversification or personal liquidity rather than a negative view on fundamentals.
Dividend, guidance and upcoming earnings
According to a recent institutional-holdings update on MarketBeat, Johnson & Johnson reported quarterly earnings per share of USD 2.90 in a recent quarter, beating the consensus estimate of USD 2.84 by USD 0.06, on revenue of USD 25.31 billion, which exceeded the consensus expectation of USD 25.06 billion and represented year-on-year revenue growth of 6.6 percent.
The same MarketBeat note states that Johnson & Johnson has set its fiscal year 2026 guidance at EPS of USD 11.60 to USD 11.75, and analysts on that platform forecast around USD 11.61 EPS for the current year, giving investors a concrete range against which to compare valuation multiples and the recent price target hikes by HSBC and RBC.
MarketBeat also highlights Johnson & Johnson’s quarterly dividend of USD 1.34 per share, which was paid on September 8, 2026 to shareholders of record on August 25, 2026, corresponding to an annualized dividend of USD 5.36 per share and a yield of roughly 2.0 percent at recent prices, with a payout ratio reported at 62.11 percent, indicating room for continued distributions alongside investment in growth.
Operational developments and regional growth
Beyond financials, Johnson & Johnson is expanding its medical devices and vision-care offerings, and on September 10, 2026 it announced that it had received CE Marking for ACUVUE OASYS MAX 2-Week reusable contact lenses for European markets, according to a press release distributed via Business Wire.
The company plans a phased rollout of ACUVUE OASYS MAX 2-Week in select European markets beginning in late 2026, with broader expansion in 2027 and 2028, subject to regulatory approvals and market readiness, which could contribute incremental growth to its vision-care segment over the coming years.
For investors, these product launches complement the core earnings story: steady revenue and earnings growth in Q2 2026, rising full-year EPS guidance, and ongoing dividend payments, all against a backdrop of strong analyst support and a valuation that some models deem stretched, making the balance between growth expectations and price an important consideration.
Stock performance and upcoming catalysts
Recent trading data compiled by CNN show Johnson & Johnson shares at USD 266.35 at a close in early September 2026, followed by modest after-hours gains of USD 0.74, while a broader earnings-call overview on Yahoo Finance lists the stock at USD 267.08 as of a close on September 9, 2026, down 0.76 percent on the day, indicating that the shares trade in a tight range near the upper end of their recent trajectory.
Yahoo Finance also reports trailing total returns for Johnson & Johnson as of September 9, 2026, with the shares up 30.77 percent year-to-date and 54.93 percent over one year versus 10.90 percent and 16.22 percent respectively for the S&P 500, underscoring that the stock has significantly outperformed the broad US equity benchmark over the past twelve months.
As for upcoming events, the Johnson & Johnson investor relations site lists an October 13, 2026 Third Quarter 2026 Earnings Call as the next major reporting date, according to Johnson & Johnson Investor Relations, giving investors a clear timeline for the next update on revenue, earnings and guidance.
Johnson & Johnson stock price snapshot
In recent sessions, Johnson & Johnson stock traded around USD 267 per share on the New York Stock Exchange, with Yahoo Finance quoting a closing price of USD 267.08 on September 9, 2026 and CNN showing a close at USD 266.35 with minor intraday fluctuations, levels that leave the stock well above its trailing twelve-month lows and within sight of recent highs, consistent with its strong one-year total return.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Trading venue: NYSE
- Price (as of September 9, 2026, 4:00 PM): 267.08 USD
- Market capitalization: (as of September 9, 2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Devices
- Index membership: S&P 500
- Next earnings date: October 13, 2026
